JP2022537515A5 - - Google Patents
Info
- Publication number
- JP2022537515A5 JP2022537515A5 JP2021573591A JP2021573591A JP2022537515A5 JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5 JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- protein according
- cancer
- antigen
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/090494 | 2019-06-10 | ||
| CN2019090494 | 2019-06-10 | ||
| PCT/CN2020/095354 WO2020249003A1 (en) | 2019-06-10 | 2020-06-10 | Antibody-interleukin fusion protein and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537515A JP2022537515A (ja) | 2022-08-26 |
| JP2022537515A5 true JP2022537515A5 (cg-RX-API-DMAC7.html) | 2023-06-19 |
Family
ID=73781610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573591A Pending JP2022537515A (ja) | 2019-06-10 | 2020-06-10 | 抗体-インターロイキン融合タンパク質および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220306713A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980067A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022537515A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114599390A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143218A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020249003A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115279793B (zh) * | 2020-05-14 | 2025-12-23 | 安立玺荣生医(香港)有限公司 | 抗pd-l1抗体和抗pd-l1/il10融合蛋白 |
| CN117377767A (zh) * | 2021-03-10 | 2024-01-09 | 免疫苏醒公司 | 免疫调节分子及其用途 |
| EP4294927A2 (en) * | 2021-03-10 | 2023-12-27 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| KR20240074772A (ko) * | 2021-10-10 | 2024-05-28 | 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 | 항-pd-l1/il-10 융합 단백질을 이용한 질병 치료 방법 |
| EP4414381A4 (en) * | 2021-11-02 | 2025-01-22 | Guangdong Fapon Biopharma Inc. | MONOMERIC FUSION PROTEIN OF IL-10 AND ITS USE |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| EP4786499A1 (en) * | 2023-10-08 | 2026-08-05 | Guangdong Fapon Biopharma Inc. | Anti-pd1-il10 fusion protein and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| KR20160079114A (ko) * | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| BR112016016658A2 (pt) * | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| SG10201901057UA (en) * | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| CN111315398A (zh) * | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
-
2020
- 2020-06-10 JP JP2021573591A patent/JP2022537515A/ja active Pending
- 2020-06-10 US US17/617,945 patent/US20220306713A1/en not_active Abandoned
- 2020-06-10 CN CN202080055588.4A patent/CN114599390A/zh active Pending
- 2020-06-10 WO PCT/CN2020/095354 patent/WO2020249003A1/en not_active Ceased
- 2020-06-10 EP EP20822767.8A patent/EP3980067A4/en not_active Withdrawn
- 2020-06-10 CA CA3143218A patent/CA3143218A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tapia-Galisteo et al. | Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies | |
| JP2022159548A5 (cg-RX-API-DMAC7.html) | ||
| JP2020103301A5 (cg-RX-API-DMAC7.html) | ||
| JP2022177097A (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| Feldmann et al. | Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells | |
| JP2022515318A5 (cg-RX-API-DMAC7.html) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2017531427A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532619A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534830A5 (cg-RX-API-DMAC7.html) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2019531697A5 (cg-RX-API-DMAC7.html) | ||
| ES3036457T3 (en) | A cd33-, cd16- and cd123-specific single chain triplebody | |
| JP2021516051A5 (cg-RX-API-DMAC7.html) | ||
| JP2021530244A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512891A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519120A5 (cg-RX-API-DMAC7.html) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2023510429A5 (cg-RX-API-DMAC7.html) | ||
| JP2015520172A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529776A5 (cg-RX-API-DMAC7.html) | ||
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| JP2019524111A5 (cg-RX-API-DMAC7.html) | ||
| IL320882A (en) | And the uses of PSMA antibodies |